EpiEndo Pharmaceuticals
epiendo.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$21.6M
1 round on record
Latest round
$21.6M
Series A · Aug 2021 · 5 yr ago
Backers
1
Flerie
The money's age
Long since its last round
61 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 24, 2021
Recognition EpiEndo Pharmaceuticals wins the Swedish American Life Sciences Summit (SALSS) Rising Star Award 2021 · businesswire.com
Aug 17, 2021
Raised a round Series A $21.6M
Feb 24, 2021
New executive EpiEndo Pharmaceuticals Appoints Maria Bech as New Chief Executive Officer to Support Move into Clinical Development · streetinsider.com
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Aug 2021 | $21.6M | — | businesswire.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Flerie Investors in similar startupsfunds that back the companies most like this one
backs Aplagon
backs Veradermics
Similar startupsby what they do, their industry and backers
About Microbiotica is a leading, clinical stage biopharmaceutical company specialising in the development of precision live biotherapeutic…
Lipum is a biopharmaceutical company specialized on a novel way to treat chronic inflammatory diseases.
Buzzard Pharmaceuticals, a clinical-stage biotech company developing innovative IL-1 targeted therapies focused on inflammation-driven…
About Us Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutics for a wide range of…
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company.
Pioneering the first oral drug for FSHD and advancing cancer treatment solutions.
News
EpiEndo Pharmaceuticals: Clinical and Pre-Clinical Data on the Novel Barriolide, EP395 (glasmacinal), Published in Three Articles in Pulmonary Pharmacology and Therapeutics
EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to inhaled
Read more
Report
Epiendo Pharmaceuticals
Research outputs, collaborations and relationships for Epiendo Pharmaceuticals
Read more
Report
Epiendo Pharmaceuticals Institution outputs
The Nature Index tracks the affiliations of high-quality scientific articles. Updated monthly, the Nature Index presents research outputs by institution and country. Use the Nature Index to interrogate publication patterns and to benchmark research perfor
Read more
Report
Report
EpiEndo Pharmaceuticals wins the Swedish American Life Sciences Summit (SALSS) Rising Star Award 2021
Read more
Report
Report
EpiEndo Pharmaceuticals Secures EUR 20 Million Series A Funding to Advance Clinical Development of its Non-Antibiotic Macrolide for the treatment of COPD
EpiEndo Pharmaceuticals (www.epiendo.com),a privately held biopharmaceutical company focused on a novel barrier enhancing approach to the treatment of chronic inflammatory airway diseases such as chronic
Read more
Report
EpiEndo Pharmaceuticals Secures EUR 20 Million Series A Funding to Advance Clinical Development of its Non-Antibiotic Macrolide for the treatment of COPD
Read more
Report
Financials
Total raised
$21.6M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2021 | $21.6M | Details |